Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05934448 · ClinicalTrials.gov registry record · Phase 2
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
A Phase 2 study of Primary Mediastinal Large B Cell Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), sponsored by Jennifer Crombie, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT05934448 is a Phase 2 study of Primary Mediastinal Large B Cell Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL) that is actively recruiting participants, run by Jennifer Crombie, MD. The registered enrollment target is 35 participants, below the 58-participant average among 11 other Primary Mediastinal Large B Cell Lymphoma trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05934448, a Phase 2 study of Primary Mediastinal Large B Cell Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), is actively recruiting participants, sponsored by Jennifer Crombie, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this study are: \- Pembrolizumab Standard treatment will include: * CAR T-cell therapy (either axicabtagene-ciloleucel or lisocabtagene maraleucel) * Cyclophosphamide * Fludarabine
Conditions Studied
Interventions
- DRUG Pembrolizumab
- PROCEDURE Leukapheresis
- DRUG Lymphodepletion Chemotherapy
- DRUG Chimeric Antigen Receptor (CAR) Therapy Infusion
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-11-15 |
| Est. Completion | 2031-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05934448
The ClinicalTrials.gov registry entry for NCT05934448 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 11 other Primary Mediastinal Large B Cell Lymphoma trials with a reported enrollment target (40% lower). The listed sponsor is Jennifer Crombie, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Primary Mediastinal Large B Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05934448 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05934448 about?
NCT05934448 is a clinical study titled "Pembro Plus CAR T-cell Therapy in R/R in PMBCL". This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has recurred after prior treatment. The names of the study drugs involved in this study are: \- Pembro...
What is the current status of trial NCT05934448?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2023-11-15. Estimated completion is 2031-06-06.
What conditions does trial NCT05934448 study?
This clinical trial studies the following conditions: Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Primary Mediastinal Large B-Cell Lymphoma Refractory.
What interventions are being tested in trial NCT05934448?
The interventions under investigation include: Pembrolizumab (DRUG), Leukapheresis (PROCEDURE), Lymphodepletion Chemotherapy (DRUG), Chimeric Antigen Receptor (CAR) Therapy Infusion (DRUG).
Who is sponsoring clinical trial NCT05934448?
This trial is sponsored by Jennifer Crombie, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05934448 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Mediastinal Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
RECRUITING · Phase 2
-
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RECRUITING
Explore more on PlainTrial
Primary Mediastinal Large B Cell Lymphoma
All registered trials for this condition
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.